A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Active, not recruiting · Phase 3 · NCT07153471
Conditions: Osteoarthritis
At a glance
- Research payments reported, 2025
- $124,581
- U.S. investigators named
- 22
- Sites paid
- 17
- Planned or actual enrollment
- 800
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Placebo (drug)
- Dates
- Started 2025-09-15; completion 2028-05
- Results posted
- Not yet
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
From ClinicalTrials.gov, last updated 2026-10-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $124,581 in research payments for this study in 2025 (29 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- William J. Reedy, MD Family Medicine · Mesa, AZ
- Louise A. Taber, M.D. Internal Medicine · Phoenix, AZ
- Elvira A. Lindwall, M.D. Rheumatology · Thousand Oaks, CA
- Christine T. Thai, M.D. Rheumatology · Huntington Beach, CA
- C D. Bird, M.D. Family Medicine · Colorado Spgs, CO
- Joseph Soufer, M.D. Internal Medicine · Waterbury, CT
- Bram Wieskopf, MD Internal Medicine · Woodstock, GA
- Thomas J. Schnitzer, MD, PHD Sports Medicine · Chicago, IL
- Martha S. Fanning, M.D. Emergency Medicine · Overland Park, KS
- David J. Dibenedetto, M.D. Pain Medicine · Waltham, MA
- Timothy R. Smith, M.D. Internal Medicine · Saint Peters, MO
- Stephen W. Jones, MD Family Medicine · Shelby, NC
- Dinesh K. Singal, M.D. Interventional Cardiology · Somerset, NJ
- Jerry L. Punch, MD Family Medicine · Knoxville, TN
- Ebere I. Azubuike, MD Family Medicine · Dallas, TX
- Ali M. Bajwa, M.D. Family Medicine · Houston, TX
- Tamar F. Brionez, MD Rheumatology · The Woodlands, TX
- Kiran Farheen, M.D. Rheumatology · Katy, TX
- Damaris Vega, MD Endocrinology & Diabetes · Houston, TX
- James R. Clark, MD Internal Medicine · Charlottesville, VA
- Steven L. Gershon, MD Pain Medicine · Virginia Beach, VA
- Aishwarya Prasad, M.D. Cardiology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Studymetrix Research LLC $43,289
- Clark Medical Research LLC $28,923
- Care Access Research LLC $20,766
- Northwest Clinical Research Center $19,618
- Gershon Consulting DBA Steven Gershon $9,962
- $334
- Intend Research LLC $334
- Biopharma Informatic Inc $223
- Heart and Vascular Center Of $129
- North Georgia Clinical Research $111
- Tamar Brionez $111
- Legacy Clinical Trials $111
- Northwestern University $111
- Great Lakes Research Group Inc $111
- Medvadis Research Corp LLC $111
- Juno Research LLC $111
- Coastal Carolina Research Center Inc $111
- Chase Medical Research LLC $111
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.